BWXT Medical
BWXT Medical Ltd. is a privately held subsidiary of BWX Technologies that manufactures pharmaceutical-grade radioisotopes and radiopharmaceutical products for diagnostic imaging and targeted cancer therapies, serving healthcare providers, pharmaceutical companies, and research institutions across 40+ countries from its CNSC-licensed facility in Kanata, Canada.
- Company typePrivate
- Founded-
- HeadquartersKanata, Canada
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What BWXT Medical does
BWXT Medical Ltd. is a radiopharmaceutical manufacturer and supplier serving the global nuclear medicine industry. It is a privately held subsidiary of BWX Technologies, Inc. (headquartered in Lynchburg, Virginia) and operates a CNSC-licensed nuclear medicine manufacturing facility in Kanata, Ontario, Canada. The company produces and distributes pharmaceutical-grade radioisotopes and radiochemical solutions used in diagnostic imaging and targeted cancer therapies, serving healthcare providers, pharmaceutical companies, and research institutions across more than 40 countries.
The company's commercial product portfolio includes Actinium-225 (an alpha-emitting therapeutic isotope), Germanium-68 Chloride Radiochemical Solution (a parent for Ga-68 PET generators), Indium-111 and Indium-111 Oxyquinoline Solution (for diagnostic imaging including infection detection), Iodine-123 and Sodium Iodide-123 Oral Solution (for thyroid imaging), and Strontium-82 (a parent for Rb-82 cardiac PET generators). An active development pipeline adds Lutetium-177 (therapeutic), Lead-203 (diagnostic), a Target Delivery System, and Technetium-99m Generators — the latter targeting the most widely used medical radioisotope globally. The company manufactures both finished products and active pharmaceutical ingredients used in end-patient diagnostic and therapeutic applications.
BWXT Medical generates revenue through direct commercial sales of radiopharmaceutical products and through related services (including regulatory compliance and manufacturing support) to enterprise buyers in the healthcare and pharmaceutical sectors. Pricing is not publicly disclosed. The go-to-market model is enterprise field sales, supported by participation in major industry events such as SNMMI, with regulated distribution requiring specialized radioactive material handling and cold-chain logistics. The company holds no public ticker, has no disclosed funding rounds, and operates within the consolidated structure of its NYSE-listed parent.
BWXT Medical firmographics
Firmographics- Name
- BWXT Medical
- Legal name
- BWXT Medical Ltd.
- Website
- https://bwxtmedical.com
- Company type
- Private
- Operating status
- Operating
- Short description
- BWXT Medical Ltd. is a privately held subsidiary of BWX Technologies that manufactures pharmaceutical-grade radioisotopes and radiopharmaceutical products for diagnostic imaging and targeted cancer therapies, serving healthcare providers, pharmaceutical companies, and research institutions across 40+ countries from its CNSC-licensed facility in Kanata, Canada.
- Ownership category
- akta.pro rank
BWXT Medical industry classification
Industry- Product category
- Radiopharmaceutical Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)
- akta.pro secondary industries
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)
Keywords
Where BWXT Medical is headquartered
LocationHeadquarters
- HQ city
- Kanata
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
BWXT Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Others
Revenue model
- Radiopharmaceutical Products: Sale of nuclear medicine products including radioisotopes and radiochemical solutions to healthcare providers and pharmaceutical companies for diagnostic and therapeutic applications
- Nuclear Medicine Services: Service offerings for the global nuclear medicine industry including regulatory compliance and manufacturing support
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BWXT Medical product offering
Product offeringCore offering
BWXT Medical develops and manufactures pharmaceutical-grade radiopharmaceutical products, including medical radioisotopes (Actinium-225, Germanium-68, Indium-111, Iodine-123, Strontium-82) and radiochemical solutions, used in nuclear medicine diagnostic imaging and targeted cancer therapies. The company also provides nuclear medicine services such as regulatory compliance support and manufacturing services, and maintains a pipeline of therapeutic radioisotopes (Lutetium-177, Lead-203) and delivery systems for the global nuclear medicine industry.
Product overview
BWXT Medical is a leading product developer and service provider for the global nuclear medicine industry. The company offers a portfolio of radiopharmaceutical products including Actinium-225 (therapeutic), Germanium-68 Chloride Radiochemical Solution, Indium-111, Indium-111 Oxyquinoline Solution, Iodine-123, Sodium Iodide-123 Oral Solution, and Strontium-82. Their product pipeline includes Lead-203, Lutetium-177, a Target Delivery System, and Technetium-99m Generators. The company manufactures both finished products and active pharmaceutical ingredients used in the production of end patient detection and treatments, enabling clinical trials and life-saving treatments in over 40 countries worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- Actinium-225 Alpha-emitting radioisotope product used in nuclear medicine for therapeutic applications, including targeted cancer therapies. Sold to healthcare providers and pharmaceutical companies for drug development.
- Germanium-68 Chloride Radiochemical Solution Radiochemical solution used as a positron emission tomography (PET) radionuclide generator parent, providing Gallium-68 for diagnostic imaging in nuclear medicine.
- Indium-111 Gamma-emitting radioisotope used in nuclear medicine imaging for diagnostic applications, including infection detection and tumor imaging.
- Indium-111 Oxyquinoline Solution Radiopharmaceutical product used for labeling white blood cells in nuclear medicine imaging for infection detection.
- Iodine-123 Radioisotope used for thyroid imaging and other diagnostic nuclear medicine procedures.
- Sodium Iodide-123 Oral Solution Oral solution formulation of Sodium Iodide-123 for thyroid diagnostic imaging.
- Strontium-82 Parent radioisotope used in generators to produce Rubidium-82 for cardiac PET imaging.
- Nuclear Medicine Services Service offerings for the global nuclear medicine industry, including regulatory compliance support and manufacturing services. Targeted at pharmaceutical companies and clinical research institutions.
Quantifiable outcome
- Patient treatments enabled in over 40 countries worldwide
- +1 more outcomes
Companies that use BWXT Medical
Customer profileSegments3 records
Ideal customer profiles2 records
BWXT Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
BWXT Medical partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Canadian Nuclear Safety Commission (CNSC)coreRegulatory relationship for compliance and oversight of the Kanata facility. BWXT Medical submits Annual Compliance Reports to CNSC as part of regulatory requirements for operating a nuclear medicine manufacturing facility.
Scale indicators3 records
Recent moves5 records
Expansion highlights8 records
BWXT Medical competitors and assessment
Company assessmentDirect peers
- NorthStar Medical Radioisotopes: U.S.-based commercial producer of Mo-99/Tc-99m and other medical radioisotopes using non-uranium production methods. Directly comparable in radioisotope manufacturing, regulatory pathway, and customer base (nuclear medicine departments and radiopharmacies).
- IBA Molecular: Specialty radiopharmaceutical producer offering PET and SPECT tracers plus isotope production technology. Direct peer in commercial radioisotope supply to hospitals and pharmaceutical partners worldwide.
- Lantheus Holdings: Specialty radiopharmaceutical company focused on diagnostic imaging agents and increasingly therapeutic radioligands (e.g., PNT2002). Comparable in commercial-stage nuclear medicine products and pharmaceutical-grade manufacturing, though larger and publicly traded.
- Curium Pharma: One of the largest commercial manufacturers of radiopharmaceuticals and nuclear medicine products globally, offering SPECT and PET isotopes and finished doses. Directly comparable to BWXT Medical across product categories, customer base, and regulatory positioning.
- Eckert & Ziegler: European-headquartered manufacturer of radiopharmaceuticals, radioisotopes, and radiation therapy sources. Comparable product portfolio across diagnostic isotopes, therapy sources, and contract manufacturing services.
Emerging players
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents (e.g., Illuccix for PSMA imaging). Comparable in targeting pharmaceutical-grade radiopharma supply for oncology and imaging customers.
Broad incumbents
- Cardinal Health (Nuclear & Precision Health Solutions): Operates the largest U.S. radiopharmacy distribution network supplying finished unit doses to hospitals. Comparable in distributing/manufacturing radiopharmaceuticals for the same healthcare-provider segment, though primarily as a downstream pharmacy rather than primary isotope producer.
- GE HealthCare (PETNET Solutions): Operates one of the largest PET tracer and SPECT isotope distribution networks via PETNET. Comparable because it supplies diagnostic nuclear medicine products to the same healthcare-provider customer base, though as part of a much broader medical-imaging portfolio.
- PETNET Solutions (Siemens Healthineers): Operates a global network of cyclotron-equipped radiopharmacy sites producing F-18, C-11 and other PET tracers. Comparable in supplying nuclear medicine diagnostic agents to hospitals and research institutions.
- Bayer (Radiology / Curium JV stake): Sells Xofigo (Ra-223) and other radiopharmaceuticals through its radiology business and has historical radiopharma joint ventures. Comparable therapeutic radiopharma franchise competing for the same oncology customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
BWXT Medical social profiles
Digital presenceBWXT Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
BWXT Medical leadership team
Management profileNumber of profiles
BWXT Medical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BWXT Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BWXT Medical
What does BWXT Medical do?
BWXT Medical develops and manufactures pharmaceutical-grade radiopharmaceutical products, including medical radioisotopes (Actinium-225, Germanium-68, Indium-111, Iodine-123, Strontium-82) and radiochemical solutions, used in nuclear medicine diagnostic imaging and targeted cancer therapies. The company also provides nuclear medicine services such as regulatory compliance support and manufacturing services, and maintains a pipeline of therapeutic radioisotopes (Lutetium-177, Lead-203) and delivery systems for the global nuclear medicine industry.
Is BWXT Medical a public or private company?
BWXT Medical is a private company. It is classified as corporate owned and is currently operating.
When was BWXT Medical founded?
BWXT Medical was founded in -1.
Where is BWXT Medical based?
BWXT Medical is headquartered in Kanata, Canada, in the North America region.
How does BWXT Medical make money?
Two revenue lines are on record. Radiopharmaceutical Products are the primary driver. The others are nuclear Medicine Services.
Who are BWXT Medical's main competitors?
Direct peers on record are NorthStar Medical Radioisotopes, IBA Molecular, Lantheus Holdings, Curium Pharma and Eckert & Ziegler. Telix Pharmaceuticals is listed as an emerging player. Broad incumbents are Cardinal Health (Nuclear & Precision Health Solutions), GE HealthCare (PETNET Solutions), PETNET Solutions (Siemens Healthineers) and Bayer (Radiology / Curium JV stake).
Does BWXT Medical have an API?
No public API is recorded for BWXT Medical.
What industry is BWXT Medical in?
BWXT Medical's product category is Radiopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 3254 and its SIC code is 2834.